MAPK
As MAPKs são uma família de proteínas quinases envolvidas em uma variedade de processos celulares, incluindo crescimento, proliferação, diferenciação e respostas ao estresse. A via de sinalização MAPK consiste em várias camadas, incluindo ERK, JNK e p38 MAPKs, cada uma desempenhando papéis distintos na função celular. A desregulação da sinalização MAPK está ligada ao câncer, doenças inflamatórias e distúrbios metabólicos. Na CymitQuimica, oferecemos uma ampla gama de inibidores e ativadores de MAPK para apoiar sua pesquisa em biologia celular, transdução de sinais e mecanismos de doenças.
Foram encontrados 881 produtos de "MAPK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
GADGVGKSA
CAS:<p>GADGVGKSA, a mutant KRAS G12D 9mer peptide, serves as an immunogenic neoantigen for cancer immunotherapy research [1].</p>Fórmula:C30H52N10O13Cor e Forma:SolidPeso molecular:760.79G12Si-5
CAS:<p>G12Si-5: covalent K-RasG12S inhibitor, Ki 26 μM, targets S-IIP domain, hinders oncogenic signaling, lowers ERK phosphorylation in mutant cells.</p>Fórmula:C31H29ClFN5O3Cor e Forma:SolidPeso molecular:574.05Cobimetinib (R-enantiomer)
CAS:<p>Cobimetinib R-enantiomer is the less active R-enantiomer of Cobimetinib which is a selective MEK inhibitor.</p>Fórmula:C21H21F3IN3O2Pureza:98%Cor e Forma:SolidPeso molecular:531.318Peraquinsin
CAS:<p>Peraquinsin is a MK2 activator that can be utilized in the research of vascular or endothelial barrier disorders and functions as an antihypertensive agent [1].</p>Fórmula:C23H28N4O4Cor e Forma:SolidPeso molecular:424.49PROTAC SOS1 degrader-4
<p>PROTAC SOS1 Degrader-4 (compound 10) is a potent degrader of SOS1 and exhibits antiproliferative activity [1].</p>Fórmula:C53H65ClN8O7SPureza:98%Cor e Forma:SolidPeso molecular:993.65HRX-0233
CAS:<p>HRX-0233 is a small molecule inhibitor targeting MAP2K4. In vivo, HRX-0233 effectively reduces tumors in H358 KRASG12C mutant non-small cell lung cancer (NSCLC) without significant toxicity. This compound also prevents feedback activation of receptor tyrosine kinases (RTKs) when used as a monotherapy with the KRAS inhibitor Sotorasib, leading to more sustained and comprehensive inhibition of the MAPK signaling pathway. HRX-0233 holds potential for research in AR-negative prostate cancer, lung cancer, and colon cancer.</p>Fórmula:C24H21F2N5O3SCor e Forma:SolidPeso molecular:497.52Anti-osteoporosis agent-8
Anti-osteoporosis agent-8 (Compound 4aa) is a RANKL inhibitor, capable of preventing RANKL-induced osteoclastogenesis and osteoclast differentiation, with an IC50 of 2.41 μM. Furthermore, Anti-osteoporosis agent-8 has been shown to mitigate bone loss in an ovariectomized (OVX) mouse model.Fórmula:C18H19F3N2O2SePeso molecular:432.05638Enniatin B1
CAS:<p>Enniatin B1, a Fusarium mycotoxin, crosses the blood-brain barrier and modulates ERK, NF-κB, and ACAT with an IC50 of 73 μM.</p>Fórmula:C34H59N3O9Pureza:98%Cor e Forma:SolidPeso molecular:653.858TAK1-IN-3
CAS:<p>TAK1-IN-3 is a novel ATP-competitive TAK1 inhibitor for the study of cancer.</p>Fórmula:C16H19N3O2SPureza:98.88%Cor e Forma:SolidPeso molecular:317.41JH295
CAS:<p>JH295: potent, selective Nek2 inhibitor (IC50 = 770 nM), irreversibly targets Cys22, no effect on Cdk1, Aurora B, Plk1, or spindle mechanisms.</p>Fórmula:C18H16N4O2Cor e Forma:SolidPeso molecular:320.352LC-2
CAS:LC-2 (PROTAC KRASG12C Degrader-LC-2) is a novel von Hippel-Lindau-based PROTAC degrader of endogenous KRAS G12C with a DC50 between 0.25 and 0.76 μM.LC-2 is aFórmula:C59H71ClFN11O7SPureza:98%Cor e Forma:SolidPeso molecular:1132.78Anti-ERK2 Antibody (5V598)
<p>Anti-ERK2 Antibody (5V598) is a Rabbit antibody targeting ERK2. Anti-ERK2 Antibody (5V598) can be used in ELISA.</p>Cor e Forma:Odour LiquidAnti-ERK2 Antibody (4F551)
<p>Anti-ERK2 Antibody (4F551) is a Rabbit antibody targeting ERK2. Anti-ERK2 Antibody (4F551) can be used in ELISA,FCM.</p>Cor e Forma:Odour LiquidAnti-ERK2 Antibody (9C922)
<p>Anti-ERK2 Antibody (9C922) is a Mouse antibody targeting ERK2. Anti-ERK2 Antibody (9C922) can be used in WB,ELISA.</p>Cor e Forma:Odour LiquidRAS GTPase inhibitor 1
CAS:RAS GTPase inhibitor 1 is a RAS GTPase inhibitor with potential antitumor activity.Fórmula:C27H28ClF4N5O2Pureza:98.43%Cor e Forma:SolidPeso molecular:565.99Enniatin B
CAS:Enniatins B decreases the activation of ERK (p44/p42).Fórmula:C33H57N3O9Pureza:98%Cor e Forma:SolidPeso molecular:639.831S6K1-IN-DG2
CAS:<p>S6K1-IN-DG2(S6K1InhibitorDG2) is a potent p70S6K inhibitor with an IC50 value of less than 100 nM.</p>Fórmula:C16H17BrN6OPureza:99.25%Cor e Forma:SolidPeso molecular:389.25TRPM4 inhibitor 8
CAS:<p>TRPM4 inhibitor 8 is an inhibitor of Transient receptor potential melastatin 4(TRPM4) which contributes to viability, migration, cell cycle shift, and adhesion.</p>Fórmula:C11H17BrN2Pureza:97%Cor e Forma:SolidPeso molecular:257.17Tunlametinib
CAS:<p>Tunlametinib is a MEK1/2 inhibitor (IC50=1.9 nM) for treating RAS/RAF-driven cancers.</p>Fórmula:C16H12F2IN3O3SPureza:98.72%Cor e Forma:SolidPeso molecular:491.25EM127
CAS:<p>EM127: covalent SMYD3 inhibitor, KD 13μM, impedes ERK1/2, hinders SMYD3 gene regulation, long-term methyltransferase reduction, potential in cancer study.</p>Fórmula:C14H18ClN3O3Pureza:97.61%Cor e Forma:SolidPeso molecular:311.76
